SLC2A3 and Alzheimer disease: These results are consistent with previous data, showing a reduction in the levels of Glut3 and its translocation to the plasma membrane in the brains of patients with AD, as well as in transgenic mouse models of AD (Simpson et al., 1994; Griffith et al., 2019).